No Evidence that


Journal

Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127

Informations de publication

Date de publication:
2022
Historique:
received: 05 05 2022
revised: 03 07 2022
accepted: 21 07 2022
entrez: 2 9 2022
pubmed: 3 9 2022
medline: 8 9 2022
Statut: epublish

Résumé

Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin, which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients with the

Identifiants

pubmed: 36051360
doi: 10.1155/2022/3132941
pmc: PMC9427256
doi:

Substances chimiques

Aminoglycosides 0
Antibodies, Monoclonal, Humanized 0
CD33 protein, human 0
Sialic Acid Binding Ig-like Lectin 3 0
Gemtuzumab 93NS566KF7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3132941

Informations de copyright

Copyright © 2022 Tamara Castaño-Bonilla et al.

Déclaration de conflit d'intérêts

T.C.B. is a PhD candidate at Universidad Autónoma de Madrid (UAM). No other conflicts of interest were declared.

Références

Blood. 2018 Jan 25;131(4):468-471
pubmed: 29229596
J Clin Oncol. 2014 Sep 20;32(27):3021-32
pubmed: 25092781
Haematologica. 2019 Jan;104(1):113-119
pubmed: 30076173
Blood. 2013 Jun 13;121(24):4854-60
pubmed: 23591789
Future Oncol. 2018 Dec;14(30):3199-3213
pubmed: 30039981
Leukemia. 2017 Sep;31(9):1855-1868
pubmed: 28607471
Biomed Pharmacother. 2018 Jan;97:225-232
pubmed: 29091870
Sci Rep. 2021 Oct 20;11(1):20745
pubmed: 34671057
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Lancet. 2012 Apr 21;379(9825):1508-16
pubmed: 22482940
Am J Hematol. 2020 Sep;95(9):E225-E228
pubmed: 32356320
Lancet Oncol. 2014 Aug;15(9):986-96
pubmed: 25008258
Minerva Med. 2020 Oct;111(5):395-410
pubmed: 32955828
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
Front Biosci (Landmark Ed). 2013 Jun 01;18(4):1311-34
pubmed: 23747885
J Clin Oncol. 2011 Feb 1;29(4):369-77
pubmed: 21172891
Expert Rev Hematol. 2016 Jan;9(1):1-3
pubmed: 26514194
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Clin Cancer Res. 2013 Mar 15;19(6):1620-7
pubmed: 23444229
Haematologica. 2021 Nov 01;106(11):2986-2989
pubmed: 34047179
Haematologica. 2019 Feb;104(2):e59-e62
pubmed: 30115657

Auteurs

Tamara Castaño-Bonilla (T)

Hematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Instituto de Investigación Sanitaria (IIS-FJD), Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.

Eva Barragán (E)

Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Claudia Sargas (C)

Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Alejandro Sanz (A)

Hematology Department, Hospital HM Sanchinarro, Madrid, Spain.

Lorenzo Algarra (L)

Hematology Department, Hospital General Universitario de Albacete, Albacete, Spain.

Pilar Herrera-Puente (P)

Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Raimundo García-Boyero (R)

Hematology Department, Hospital General de Castellón, Castellón de la Plana, Spain.

Manuel Barrios (M)

Hematology Department, Hospital Regional Universitario de Málaga, Málaga, Spain.

David Martinez-Cuadron (D)

Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Rebeca Rodriguez-Veiga (R)

Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Blanca Boluda (B)

Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Cristina Gil (C)

Hematology Department, Hospital General Universitario de Alicante, Alicante, Spain.

Josefina Serrano-López (J)

Hematology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.

Joaquín Martínez-López (J)

Hematology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.

María José Sayas-Lloris (MJ)

Hematology Department, Hospital Universitario Doctor Peset, Valencia, Spain.

María Teresa Olave (MT)

Hematology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

Rosalía Riaza-Grau (R)

Hematology Department, Hospital Universitario Severo Ochoa, Madrid, Spain.

Teresa Bernal-Del Castillo (TB)

Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

María José Larrayoz (MJ)

Molecular Biology Department, Cimalab Diagnosis, Clínica Universitaria de Navarra, Pamplona, Spain.

Raquel Amigo (R)

Biobanco La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.

Antonio Jiménez-Velasco (A)

Hematology Department, Hospital Regional Universitario de Málaga, Málaga, Spain.

Joaquín Sánchez (J)

Hematology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.

Rosa Ayala (R)

Hematology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.

Carlos Blas (C)

Hematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Instituto de Investigación Sanitaria (IIS-FJD), Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.

Daniel Lainez (D)

Instituto de Investigación Sanitaria (IIS-FJD), Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.

Juana Serrano-López (J)

Instituto de Investigación Sanitaria (IIS-FJD), Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.

Miguel A Sanz (MA)

Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Juan M Alonso-Domínguez (JM)

Hematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Instituto de Investigación Sanitaria (IIS-FJD), Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.

Pau Montesinos (P)

Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH